AngioDynamics, Inc. reported a notable increase in financial performance for the second quarter of fiscal year 2026, with net sales reaching $79.4 million, a 9.0% increase from $72.8 million in the same quarter of the previous year. For the six months ending November 30, 2025, total revenue rose by 10.6% to $155.1 million compared to $140.3 million in the prior year. The company’s gross margin also improved, increasing to 56.4% from 54.8% year-over-year, driven by enhanced sales volume and product mix.
The company experienced a reduction in net loss, which decreased by $4.4 million to $6.4 million for the three months ended November 30, 2025, compared to a loss of $10.7 million in the same period last year. For the six-month period, the net loss was $17.3 million, down from $23.5 million. Loss per share also improved, decreasing to $0.15 from $0.26 for the quarter and to $0.42 from $0.58 for the six months.
Strategically, AngioDynamics has focused on expanding its product offerings, particularly in its Med Tech and Med Device segments. The Med Tech segment, which includes products like Auryon and NanoKnife, saw a revenue increase of 13.0% for the quarter, while the Med Device segment grew by 6.0%. The company has also been actively managing its operational costs, with total operating expenses slightly decreasing to $50.9 million from $51.0 million in the previous year.
Operationally, AngioDynamics reported a backlog of $0.4 million as of November 30, 2025, and noted that its international sales accounted for approximately 14.9% of total net sales for the quarter. The company continues to invest in research and development, with R&D expenses rising to $7.8 million for the quarter, reflecting a commitment to innovation and product enhancement. The workforce has also seen growth, with a slight increase in employee headcount contributing to the company's operational capabilities.
Looking ahead, AngioDynamics remains optimistic about its growth trajectory, emphasizing plans for geographic expansion and the introduction of new products. The company is closely monitoring macroeconomic conditions, including inflation and supply chain challenges, which may impact future performance. Management believes that the current cash balance of $41.6 million, along with cash generated from operations, will provide sufficient liquidity to meet anticipated capital needs for at least the next 12 months.
About ANGIODYNAMICS INC
AngioDynamics, Inc. is a diversified medical technology company focused on enhancing treatment options for cardiovascular diseases and cancer. Its key products include the Auryon Atherectomy System and various thrombus management devices. With a growing market opportunity, AngioDynamics targets interventional radiologists and oncologists. The company emphasizes innovation through R&D and strategic acquisitions, aiming to improve patient outcomes and expand its product offerings in the competitive medical device landscape.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.